YTHDF2 and pachyonychia congenita: Taken together, PJA2 acted as a tumor suppressor to regulate PC malignant behaviors via the FTO–PJA2–Wnt axis in an m6A-YTHDF2-dependent way, indicating that PJA2 is a new promising molecular target for PC therapeutic treatment.